Alan H. Auerbach, who serves as both President and CEO of Puma Biotechnology, Inc. (NASDAQ:PBYI), executed a sale of company common stock on July 6, 2026. Mr. Auerbach also holds a position on the company's Board of Directors and maintains a ten percent ownership stake in the enterprise.
The transaction involved the disposal of 44,058 shares of Puma Biotechnology common stock. These shares were sold at a price of $8.263 per share, resulting in total proceeds of $364,051. The sale was conducted under the parameters of a Rule 10b5-1 trading plan, a pre-arranged framework established by Mr. Auerbach on December 17, 2020. This structured approach to selling shares is designed to facilitate transactions in compliance with insider trading regulations.
The timing of this insider sale is notable given the current market context for Puma Biotechnology. The stock has been trading near its 52-week high of $8.44. This price level follows a significant 126% gain over the past year. According to analysis from InvestingPro, the stock currently appears undervalued, with a calculated Fair Value of $13. This valuation suggests potential upside for investors, even as the top executive reduces their holding through this specific transaction.
Following the execution of this sale, Mr. Auerbach's direct holdings in Puma Biotechnology common stock stand at 7,261,671 shares. For investors seeking deeper insights into PBYI's financial health and growth prospects, comprehensive Pro Research Reports are available exclusively on InvestingPro for this equity and over 1,400 other US equities.
In other recent developments, Puma Biotechnology reported its first-quarter 2026 earnings, which revealed a net loss per share that did not meet analyst expectations. Revenue figures for the quarter also fell short of forecasts. The company posted an earnings per share of -$0.04, missing the forecasted $0.00. Revenue for the quarter was recorded at $44.8 million, which was below the anticipated $49 million, marking a revenue surprise of -8.57%.
Additionally, Puma Biotechnology held its 2026 Annual Meeting of Stockholders. During this meeting, shareholders elected eight directors to serve one-year terms until the next annual meeting in 2027. The elected directors include Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson. Voting results showed a range of 32,546,955 to 37,472,173 shares in favor, with between 444,129 and 5,369,347 shares withheld. There were also 6,064,713 broker non-votes for each nominee.
Puma Biotech stock data indicates a closing price of 8.13, reflecting a +0.170 (+2.14%) movement. After hours trading showed a price of 8.130 with 0.000 (0.00%) movement. These developments are part of the company's recent activities.